Payment overview · 2025
General Payments
$1,269.52
65 reported records · 27 companies
Healthcare provider profile · identity verified
Jose A L Monteiro, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FALL RIVER, MA · NPI 1548203219
Verified facts
What the public records show
CMS Open Payments records show Jose A L Monteiro, MD received $1,269.52 in general payments during 2025 across 65 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ibsrela, Kerendia, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Voquezna, Vraylar, Yupelri.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Vraylar by this doctor in 2024.
Ardelyx, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBSRELA as an associated drug or biological on 59980 records involving 18215 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ibsrela by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexium by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 391 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 310 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 391 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nurtec Odt by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Voquezna by this doctor in 2024.
Viatris Specialty LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported YUPELRI as an associated drug or biological on 26927 records involving 11152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Yupelri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $155.48 | 12.2% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $139.62 | 11.0% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $81.29 | 6.4% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $78.94 | 6.2% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $76.71 | 6.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.07 | 5.5% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $66.34 | 5.2% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $65.72 | 5.2% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $64.02 | 5.0% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $56.34 | 4.4% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.75 | 4.3% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $41.51 | 3.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.47 | 2.6% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $32.90 | 2.6% | 1 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $31.09 | 2.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.07 | 2.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $28.79 | 2.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.36 | 1.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.70 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.28 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.00 | 1.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.49 | 1.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.02 | 1.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.17 | 1.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.15 | 1.1% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.84 | 1.1% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $8.40 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,269.52 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $139.62 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $88.55 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $76.71 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.07 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $70.07 | 3 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $66.34 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $65.72 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $64.02 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $58.13 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $56.34 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $54.75 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $44.45 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $41.51 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.77 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.77 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.77 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $34.49 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.47 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $32.90 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $31.07 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $28.79 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $8.80 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $8.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 391 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 227 | exact normalized | Medicare Part D |
| IBSRELA ibsrela |
2025 | Ibsrela | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 84 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 310 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 81 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 78 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 134 | exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| YUPELRI yupelri |
2025 | Yupelri | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
184 | 48 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Ardelyx, Inc. Exact reporting entity; no affiliate inference |
2025 | IBSRELA open payments reported associated product |
CMS Open Payments — General Payments 59980 supporting records · 18215 recipient NPIs · example record 1247828901 |
Ibsrela · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
227 | 65 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
391 | 77 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
134 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
272 | 58 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
84 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
96 | 21 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
310 | 72 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
78 | 27 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
81 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
391 | 77 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Viatris Specialty LLC Exact reporting entity; no affiliate inference |
2025 | YUPELRI open payments reported associated product |
CMS Open Payments — General Payments 26927 supporting records · 11152 recipient NPIs · example record 1238463489 |
Yupelri · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1129 | 301 |
| Lisinopril | Lisinopril | 1069 | 302 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 846 | 243 |
| Omeprazole | Omeprazole | 777 | 204 |
| Furosemide | Furosemide | 695 | 205 |
| Metoprolol Succinate | Metoprolol Succinate | 670 | 179 |
| Levothyroxine Sodium | Levothyroxine Sodium | 620 | 161 |
| Pantoprazole Sodium | Pantoprazole Sodium | 585 | 167 |
| Losartan Potassium | Losartan Potassium | 571 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 503 | 137 |
| Sertraline Hcl | Sertraline Hcl | 466 | 126 |
| Carvedilol | Carvedilol | 416 | 106 |
| Eliquis | Apixaban | 391 | 77 |
| Allopurinol | Allopurinol | 381 | 111 |
| Gabapentin | Gabapentin | 359 | 94 |
| Simvastatin | Simvastatin | 313 | 93 |
| Ozempic | Semaglutide | 310 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 292 | 82 |
| Xarelto | Rivaroxaban | 287 | 60 |
| Jardiance | Empagliflozin | 272 | 58 |
| Potassium Chloride | Potassium Chloride | 260 | 68 |
| Glipizide Er | Glipizide | 255 | 65 |
| Indapamide | Indapamide | 251 | 77 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 250 | 85 |
| Farxiga | Dapagliflozin Propanediol | 227 | 65 |
| Montelukast Sodium | Montelukast Sodium | 223 | 73 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 213 | 49 |
| Quetiapine Fumarate | Quetiapine Fumarate | 208 | 37 |
| Metformin Hcl Er | Metformin Hcl | 206 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 202 | 45 |
| Lorazepam | Lorazepam | 191 | 59 |
| Meclizine Hcl | Meclizine Hcl | 190 | 58 |
| Citalopram Hbr | Citalopram Hydrobromide | 189 | 49 |
| Prednisone | Prednisone | 186 | 102 |
| Linzess | Linaclotide | 184 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 61 |
| Diclofenac Sodium | Diclofenac Sodium | 173 | 77 |
| Trazodone Hcl | Trazodone Hcl | 168 | 41 |
| Labetalol Hcl | Labetalol Hcl | 158 | 43 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 152 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 34 |
| Spironolactone | Spironolactone | 137 | 37 |
| Finasteride | Finasteride | 136 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 134 | 38 |
| Celecoxib | Celecoxib | 132 | 55 |
| Calcitriol | Calcitriol | 130 | 30 |
| Baclofen | Baclofen | 123 | 54 |
| Alendronate Sodium | Alendronate Sodium | 121 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 53 |
| Warfarin Sodium | Warfarin Sodium | 119 | 27 |
| Metformin Hcl | Metformin Hcl | 115 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 28 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 106 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 29 |
| Mirtazapine | Mirtazapine | 98 | 24 |
| Tresiba Flextouch U-200 | Insulin Degludec | 97 | 27 |
| Trulicity | Dulaglutide | 96 | 21 |
| Clonazepam | Clonazepam | 89 | 13 |
| Mounjaro | Tirzepatide | 84 | 23 |
| Famotidine | Famotidine | 83 | 24 |
| Nitroglycerin | Nitroglycerin | 83 | 37 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 22 |
| Rexulti | Brexpiprazole | 81 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 21 |
| Bumetanide | Bumetanide | 79 | 21 |
| Rybelsus | Semaglutide | 78 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 76 | 22 |
| Fenofibrate | Fenofibrate,micronized | 72 | 17 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 71 | 21 |
| Metoclopramide Hcl | Metoclopramide Hcl | 71 | 24 |
| Tramadol Hcl | Tramadol Hcl | 69 | 27 |
| Pregabalin | Pregabalin | 67 | 11 |
| Valsartan | Valsartan | 67 | 16 |
| Donepezil Hcl | Donepezil Hcl | 65 | 13 |
| Folic Acid | Folic Acid | 63 | 12 |
| Lamotrigine | Lamotrigine | 62 | 13 |
| Clotrimazole | Clotrimazole | 61 | 38 |
| Dexlansoprazole Dr | Dexlansoprazole | 61 | 18 |
| Tresiba Flextouch U-100 | Insulin Degludec | 61 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 11 |
| Glyxambi | Empagliflozin/Linagliptin | 57 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 19 |
| Nifedipine Er | Nifedipine | 55 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 14 |
| Humalog Kwikpen U-200 | Insulin Lispro | 53 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 52 | 15 |
| Repatha Sureclick | Evolocumab | 52 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 44 |
| Oxycodone Hcl | Oxycodone Hcl | 50 | 29 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 30 |
| Atenolol | Atenolol | 46 | 12 |
| Januvia | Sitagliptin Phosphate | 46 | 14 |
| Klor-Con M20 | Potassium Chloride | 46 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 13 |
| Levofloxacin | Levofloxacin | 45 | 35 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 44 | 26 |
| Amiodarone Hcl | Amiodarone Hcl | 43 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 43 | 20 |
| Hydrocortisone | Hydrocortisone | 43 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 40 | suppressed |
| Kerendia | Finerenone | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | 11 |
| Sucralfate | Sucralfate | 39 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 38 | 36 |
| Nystatin | Nystatin | 38 | 23 |
| Sotalol | Sotalol Hcl | 38 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 38 | 14 |
| Colchicine | Colchicine | 37 | 20 |
| Novolog Flexpen | Insulin Aspart | 37 | 13 |
| Prazosin Hcl | Prazosin Hcl | 37 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 36 | suppressed |
| Fluconazole | Fluconazole | 36 | 29 |
| Glimepiride | Glimepiride | 35 | suppressed |
| Alprazolam | Alprazolam | 34 | suppressed |
| Ketoconazole | Ketoconazole | 34 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 34 | 19 |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Lactulose | Lactulose | 31 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | suppressed |
| Levemir Flexpen | Insulin Detemir | 30 | 15 |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Prolia | Denosumab | 29 | 18 |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 28 | 22 |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Jantoven | Warfarin Sodium | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Vraylar | Cariprazine Hcl | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Voquezna | Vonoprazan Fumarate | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 15 |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 24 | 12 |
| Azithromycin | Azithromycin | 23 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | 14 |
| Admelog Solostar | Insulin Lispro | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Constulose | Lactulose | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | 13 |
| Nitroglycerin Patch | Nitroglycerin | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Glipizide | Glipizide | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | 11 |
| Metolazone | Metolazone | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 17 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 19 | 16 |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Unifine Pentips Plus | Pen Needle, Diabetic | 19 | suppressed |
| Acarbose | Acarbose | 18 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 18 | suppressed |
| Dexamethasone | Dexamethasone | 18 | 16 |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 16 | suppressed |
| Captopril | Captopril | 15 | suppressed |
| Desvenlafaxine Er | Desvenlafaxine | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Eplerenone | Eplerenone | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Nexium | Esomeprazole Magnesium | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | 13 |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Ibsrela | Tenapanor Hcl | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Austedo | Deutetrabenazine | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 12 |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Motegrity | Prucalopride Succinate | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Advocate Pen Needles | Pen Needle, Diabetic | 11 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 11 | suppressed |
| Yupelri | Revefenacin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,269.52 · 65 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AMVUTTRA, AREXVY, BREZTRI, CAMZYOS, CAPLYTA, CAPVAXIVE, COMIRNATY, CeQur Simplicity, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, IBSRELA, INGREZZA, Kerendia, Korlym, LAGEVRIO, LEQVIO, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, PREVNAR 20, Prolastin-C Liquid, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VERQUVO, VOQUEZNA, VRAYLAR, VYNDAMAX, YUPELRI, ZAVZPRET, ZEPBOUND, ZORYVE | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error